(Q33639790)

28 July 2017

1 reference

title

Cytochrome P450-based cancer gene therapy: recent advances and future prospects (English)

1 reference

28 July 2017

0 references

1 reference

1

1 reference

28 July 2017

Chen L

2

1 reference

28 July 2017

Hecht JE

series ordinal

3

1 reference

28 July 2017

Jounaidi Y

series ordinal

4

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 May 1999

1 reference

28 July 2017

Drug Metabolism Reviews

1 reference

28 July 2017

31

1 reference

28 July 2017

503-522

1 reference

28 July 2017

2

1 reference

Gene therapy for cancer: what have we done and where are we going?

28 July 2017

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

The role of the bystander effect in suicide gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

Regression of established macroscopic liver metastases after in situ transduction of a suicide gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

Interaction of anticancer drugs with hepatic monooxygenase enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

Metabolism of oxazaphosphorines

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

Gene introduction into animal tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

NADPH-cytochrome P-450 oxidoreductase gene organization correlates with structural domains of the protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

NADPH cytochrome P-450 oxidoreductase gene: identification and characterization of the promoter region

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

An unusual yet strongly conserved flavoprotein reductase in bacteria and mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

Regulation of rat hepatic cytochrome P-450: age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isoenzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

The experimental development of bioreductive drugs and their role in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

Viral vectors for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

Cancer gene therapy by direct tumor injections of a nonviral T7 vector encoding a thymidine kinase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

Progress in transcriptionally targeted and regulatable vectors for genetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

Targeting gene expression to hypoxic tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-100101933

21 January 2018

Identifiers

DOI

10.1081/DMR-100101933

1 reference

28 July 2017

1 reference